-
公开(公告)号：KR1020090122344A
公开(公告)日：2009-11-27
申请号：KR1020097016858
申请日：2008-02-15
IPC: A61K9/10 , A61K9/16 , A61K31/4709 , A61P7/02
CPC classification number: A61K9/2054 , A61K9/1635 , A61K9/1652 , A61K9/1694 , A61K9/205 , A61K9/2077 , A61K31/4709
Abstract: PURPOSE: A controlled release agent containing cilostazol and a method for producing the same are provided to maintain the effective drug concentration in blood and improve medicine compliance. CONSTITUTION: A controlled release agent of cilostazol comprise a solid dispersion granule containing 10-80 weight% of cilostazol and 0.1-50 weight% of solubilizing agent and 5-80 weight% of hydrogel forming material. A method for producing the controlled release agent of cilostazol comprises: a step of mixing cilostazol or its pharmaceutically acceptable salt and solubilizing agent to granulate; and a step of mixing the drug granule with hydrogel than granulating.
Abstract translation: 目的：提供含有西洛他唑的控释药及其制备方法，以维持血液中有效的药物浓度，提高药物依从性。 构成：西洛他唑的控释药物包含固体分散颗粒，其含有10-80重量％的西洛他唑和0.1-50重量％的增溶剂和5-80重量％的水凝胶形成材料。 西洛他唑控制释放剂的制备方法包括：将西洛他唑或其药学上可接受的盐和增溶剂混合成粒状的步骤; 以及将药物颗粒与水凝胶混合的步骤，而不是制粒。
-
公开(公告)号：KR1020080076382A
公开(公告)日：2008-08-20
申请号：KR1020070016221
申请日：2007-02-15
IPC: A61K9/22 , A61K31/4709
CPC classification number: A61K9/0065 , A61K9/2031 , A61K9/2054 , A61K31/4709
Abstract: A controlled-release preparation containing cilostazol is provided to improve absorption rate of cilostazol in small intestine and reduce side effects such as headache by staying in stomach for a long time and slowly releasing cilostazol, and enhance compliance of patient by reducing dosage frequency. A controlled-release preparation contains 10-80 wt.% of cilostazol or its pharmaceutically acceptable salt, 0.1-50 wt.% of solubilizer, 5-80 wt.% of swelling agent, 0.5-50 wt.% of swelling speed-controller and 0.1-50 wt.% of gas-generating material. A method for preparing the controlled-release preparation containing cilostazol comprises the steps of: mixing cilostazol or its pharmaceutically acceptable salt, solubilizer, swelling agent, swelling speed-controller and gas-generating material; granulating the mixture; and filling the granulates in capsules or tabletting the granulates.
Abstract translation: 提供含有西洛他唑的控释制剂，以提高西洛他唑在小肠中的吸收率，并通过长时间停留在胃中并缓慢释放西洛他唑，减少头痛的副作用，并通过降低剂量频率增强患者的依从性。 控释制剂含有10-80重量％的西洛他唑或其药学上可接受的盐，0.1-50重量％的增溶剂，5-80重量％的溶胀剂，0.5-50重量％的溶胀速度控制剂 和0.1-50重量％的气体发生材料。 制备含有西洛他唑的控释制剂的方法包括以下步骤：将西洛他唑或其药学上可接受的盐，增溶剂，溶胀剂，溶胀速度控制器和产气材料混合; 制粒混合物; 并将颗粒填充在胶囊中或压制颗粒。
-
公开(公告)号：KR101729140B1
公开(公告)日：2017-04-26
申请号：KR1020100085038
申请日：2010-08-31
Applicant: (주)아모레퍼시픽
IPC: C08K5/20 , C08L33/00 , C08J3/12 , A61K31/194
Abstract: 본발명은분지쇄아미노산및 카르복실기를포함하는고분자화합물을포함하는조성물을개시한다. 상기조성물은아미노산의쓴 맛또는냄새가차폐되어복용하기편리하다. 또한본 발명은분지쇄아미노산과카르복실기를포함하는고분자화합물을혼합하는단계를포함하는분지쇄아미노산의쓴 맛또는냄새차폐방법을개시한다.
Abstract translation: 本发明公开了包含含有支链氨基酸和羧基的聚合物的组合物。 该组合物很容易摄入，因为它可以防止苦味或氨基酸的味道。 本发明还公开了支链氨基酸的苦味或气味遮蔽方法，其包括混合包含支链氨基酸和羧基的聚合物化合物的步骤。
-
Patent Agency Ranking
公开(公告)号：KR1020160101554A
公开(公告)日：2016-08-25
申请号：KR1020150024334
申请日：2015-02-17
Applicant: (주)아모레퍼시픽
IPC: C07C303/36 , C07C311/08 , C07C303/42
CPC classification number: C07C303/36 , C07C303/42 , C07C311/08
Abstract: 본명세서는비대칭탄소원자에아민기가결합된화합물의입체이성질체혼합물을카이랄보조체및 염-형성보조화합물과혼합시키는단계를포함하는입체이성질체혼합물의카이랄분할방법에관한것이다. 이때, 카이랄보조체는 2,3-디벤조일-타르타르산또는-디--톨루오일타르타르산이고, 염-형성보조화합물은만델산또는캄포르술폰산이며, 이러한방법에의하면높은수준의광학순도를가지는광학이성질체를얻는것이가능하다. 따라서, 본발명의일 측면에따른방법은약학또는제약분야에서단일한형태의광학이성질체를가지는화합물을높은순도로수득하고자하는경우에유용하게사용될수 있다.
Abstract translation: 本发明涉及立体异构体混合物的手性拆分方法，其包括将通过与不对称碳原子连接的胺基组成的化合物的立体异构体混合物与手性助剂和成盐助剂混合的步骤 复合。 同时，手性助剂为2,3-二苯甲酰酒石酸或O，O-二对甲苯酰酒石酸。 形成盐的辅助化合物是扁桃酸或樟脑磺酸。 根据本发明，可以得到光学纯度高的光学异构体。 因此，当以高纯度获得具有单一类型的光学异构体的化合物时，根据本发明的一个方面的方法可以有用地用于药房或药物领域。
-
公开(公告)号：KR200464913Y1
公开(公告)日：2013-01-31
申请号：KR2020110010216
申请日：2011-11-17
CPC classification number: A61H23/02 , A61F7/02 , A61F7/034 , A61H2201/0207 , A61H2201/0228 , A61H2201/165 , A61K9/7038 , A61N1/0408 , A61N1/0472 , A61N1/0492 , A61N1/32
Abstract: 본 고안은 관절부위와 같이 부착이 어려운 환부에 용이하게 부착할 수 있게 구성된 진동 자극 패드에 관한 것으로서, 본 고안의 진동 자극 패드는, 플레시블한 몸체와, 상기 몸체의 하면에 부착되며 소염.진통제로 이루어진 약품이 혼합된 점착제로 구성되는 약제층과, 상기 몸체의 상면에 부착되며 진동모터 및 배터리를 구비하는 진동모듈 그리고 상기 몸체의 둘레를 따라 설치되는 점착력이 부가된 복수의 다리를 포함하여 구성되며, 이러한 구성을 통해 플렉시블 소재로 형성된 몸체와 상기 몸체의 둘레를 따라 부착되며 점착력이 부가된 복수의 다리에 의해 관절부위와 같이 부착이 어려운 환부에 용이하게 부착할 수 있는 효과를 제공한다.
-
公开(公告)号：KR1020110075011A
公开(公告)日：2011-07-05
申请号：KR1020117010529
申请日：2009-11-10
Applicant: (주)아모레퍼시픽
CPC classification number: A61K9/5047 , A61K9/5026 , A61K9/5042 , A61K9/16 , A61K47/50
Abstract: PURPOSE: A sustained release fine particle containing a matrix containing pharmaceutically active ingredients and a sustained release layer is provided to ensure excellent elution effect. CONSTITUTION: A sustained release fine particle comprises: a matrix containing pharmacologically active ingredients; and a sustained release layer containing a sustained release membrane forming material on the matrix. The sustained release membrane forming material is a water insoluble polymer, enteric polymer, soluble polymer, or mixture thereof. The insoluble polymer is ethyl cellulose, cellulose ether, acrylic acid ethyl-methacrylic acid methyl-methacrylic acid trimethyl ammonium ethyl chloride copolymer, polyvinyl acetate, and acrylic acid ethyl-methacrylic acid methyl copolymer or dispersion solution thereof. The soluble polymer is hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinyl pyrolidone, or polyvinyl alcohol. The matrix further contains an excipient or binder.
Abstract translation: 目的：提供含有含有药物活性成分和持续释放层的基质的缓释微粒，以确保优异的洗脱效果。 构成：缓释微粒包括：含有药理活性成分的基质; 以及在基质上含有缓释膜形成材料的持续释放层。 缓释膜形成材料是水不溶性聚合物，肠溶聚合物，可溶性聚合物或其混合物。 不溶性聚合物是乙基纤维素，纤维素醚，丙烯酸乙基 - 甲基丙烯酸甲基 - 甲基丙烯酸三甲基铵乙基氯共聚物，聚乙酸乙烯酯和丙烯酸乙基 - 甲基丙烯酸甲基共聚物或其分散溶液。 可溶性聚合物是羟丙基纤维素，羟丙基甲基纤维素，聚乙烯吡咯烷酮或聚乙烯醇。 基质还含有赋形剂或粘合剂。
-
公开(公告)号：KR1020100052253A
公开(公告)日：2010-05-19
申请号：KR1020080111190
申请日：2008-11-10
Applicant: (주)아모레퍼시픽
CPC classification number: A61K31/41 , A61K9/0053 , A61K9/2095
Abstract: PURPOSE: A method for manufacturing a solid oral formulation containing valsartan is provided to effectively obtain an oral formulation having excellent disintegration force and dissolution rate. CONSTITUTION: A method for manufacturing a solid oral formulation containing valsartan comprises: a step of contacting valsartan and pharmaceutically acceptable additive with binding solution; a step of drying resultant; a step of granulating the dried resultant; and a step of mixing the granule with disintegrant and lubricant. The binding solution is water, or mixture of water and ethanol. The disintegrant is crospovidone.
Abstract translation: 目的：提供一种制备含缬沙坦固体口服制剂的方法，以有效获得具有优异的崩解力和溶出率的口服制剂。 构成：制备含缬沙坦的固体口服制剂的方法包括：将缬沙坦和药学上可接受的添加剂与结合溶液接触的步骤; 干燥结果的步骤; 造粒干燥物的步骤; 以及将颗粒与崩解剂和润滑剂混合的步骤。 结合溶液是水，或水和乙醇的混合物。 崩解剂是交聚维酮。
-
公开(公告)号：KR1020060053972A
公开(公告)日：2006-05-22
申请号：KR1020050066153
申请日：2005-07-21
Applicant: (주)아모레퍼시픽
IPC: A61K9/16 , A61K9/22 , A61K31/357
CPC classification number: A61K9/2027 , A61K9/2077
Abstract: 본 발명은 토피라메이트 서방성 제제 및 그의 제조방법에 관한 것이다.
즉, 본 발명은 토피라메이트 또는 그의 약제학적으로 허용가능한 염을 고체분산 첨가제를 사용하여 고체 분산법에 의해 1차 과립화 시키고, 얻어진 과립을 서방화 물질로 건식 혹은 습식과립법에 의해 2차 과립화 하여 얻은 이중 과립을 이용하여 제조됨을 특징으로 하는 서방성 제제에 관한 것이다.
서방성 제제, 고체 분산법, 이중과립, 토피라메이트
-
-
-
-
-
-
-
Search Results
28
records
(took 0.048 seconds)
